Ebola vaccines require greater speed in trials

Successful containment efforts in Africa have an unavoidable consequence.

By Nicole Gray • June 18, 2015

Synergy Pharma shares soar from constipation drug study

Positive results on the efficacy of Plecanatide, Synergy's lead drug, pushed the stock up 66% yesterday.

By Nicole Gray • June 18, 2015

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

By BioPharma Dive staff

Avalanche gene therapy safe, modestly effective in AMD patients

The biotech also has a potential deal in place with Regeneron. 

By Nicole Gray • June 16, 2015

The curious case of Lilly's share price and its Alzheimer's hopeful data

There is a great deal of excitment surrounding the company's investigational Alzheimer's drug, solanezumab.

By Nicole Gray • June 15, 2015

1st sickle cell patient treated with Bluebird's pioneering gene therapy doing well

A 13-year-old French boy with sickle cell anemia is the first patient to be treated with Bluebird Bio's Lentiglobin BB305. 

By Nicole Gray • June 15, 2015

Massive study: Merck's diabetes mega-blockbuster doesn't increase heart failure risk

Results from TECOS, which included more than 14,000 patients, showed no increased risk of heart problems in general.

By Nicole Gray • June 11, 2015

Biosim war heats up as Merck's Remicade & Enbrel biosimilars bag major wins in RA

The pharma giant and Samsung Bioepis are collaborating on biosimilars of five of the top-selling drugs in the world.

By Sy Mukherjee • June 10, 2015

Lilly's Trulicity and Novo's IDegLira best Lantus in trials

The double-whammy might be of concern to Sanofi.

By Nicole Gray • June 9, 2015

Massive new study: The statin-memory lapse connection may be unfounded

That would be great news for millions of patients.

By Nicole Gray • June 9, 2015

Titan Pharma's opioid addiction implant shows promise in phase III

After a 2013 rejection by the FDA, the company and its partner Braeburn Pharmaceuticals are giving Probuphine another go.

By Sy Mukherjee • June 8, 2015

Report: Metformin decreases glaucoma risk in older adults

A daily 1.5-gram dose of metformin over two years decreased the risk of glaucoma by 25% in diabetics.

By Nicole Gray • June 5, 2015

NCI launching largest-ever personalized medicine study for cancer drugs

The effort aims to match mutations with existing drugs.

By Nicole Gray • June 3, 2015

A final ASCO15 roundup: Docs slam prices for meds, ImmunoGen eyes redemption, Puma gets hammered

The massive annual oncology meeting is coming to a close. Here's what you need to know. 

By Sy Mukherjee • June 2, 2015

ASCO15: BMS' new standard for melanoma, Celldex's brain cancer vax, Clovis' ovarian cancer win

The data deluge continued on ASCO Sunday, with a lot of promising news from large and smaller companies alike. Here's what you need to know.

By Sy Mukherjee • May 31, 2015

Your ASCO15 guide: A mixed bag for Bristol-Myers, big wins for Merck, J&J

The American Society of Clinical Oncology mega-conference started off with a bang this weekend. Here are the ups, downs, and most important developments you need to know about.

By Sy Mukherjee • May 30, 2015

New evidence-based consensus: Start HIV treatment at diagnosis

In a trial, newly diagnosed HIV patients who started treatment immediately were 53% less likely to develop AIDS or die. 

By Nicole Gray • May 29, 2015

Otonomy's inner-ear drug flops in trials

The company has been developing OTO-104 for treatment of Meniere's disease, which leads to deafness, vertigo, and ringing in the ears.

By Nicole Gray • May 22, 2015

Sanofi/Regeneron's arthritis drug nails it in phase III

A regulatory filing is expected in Q4 of this year.

By Nicole Gray • May 22, 2015

Bluebird shares more data on its breakthrough gene therapy trials, and it continues to impress

The sample size is still small. But patients with beta-thalassemia and severe sickle cell disease are responding quite well to the treatment with no adverse effects so far.

By Sy Mukherjee • May 22, 2015

Study: Tylenol use during pregnancy may lower testosterone in male offspring

But some are warning to take the study with a grain of salt, as it was conducted in mice.

By Nicole Gray • May 21, 2015

GW Pharma moves CEO to US to lay groundwork for cannabis-epilepsy med approval

Justin Gover is moving from London, where GW is headquartered, to Southern California. And the company's riding high off results from an epilepsy trial.

By Nicole Gray • May 20, 2015

Sanofi/Regeneron reports glowing phase 2b results for versatile asthma hopeful

Earlier this year, Sanofi EVP Pascale Witz told BioPharma Dive that dupilumab was one of the company's most exciting in-development products thanks to its potential in multiple, diverse therapeutic categories.

By Nicole Gray • May 20, 2015

Bluebird cuts deal with regulators, plots path to first-ever US gene therapy approval

The biotech's gene therapy LentiGlobin for beta-thalassemia will have an accelerated approval pathway in the U.S. and Europe. 

By Sy Mukherjee • May 19, 2015

Amgen boasts promising phase II results for migraine drug

But the candidate would enter a busy therapeutic field.

By Nicole Gray • May 18, 2015

Hotly anticipated AZ lung cancer combo effective, but side effects remain a problem

The British pharma giant will be unveiling full data during the American Society of Clinical Oncology (ASCO) conference at the end of May.

By Nicole Gray • May 15, 2015